180+
AATD Patients Successfully Recruited
7+
Completed Alpha-1 Studies
68%
Faster Enrollment Than Industry Average
96%
Patient Retention Rate in AATD Trials
Alpha-1 Antitrypsin Deficiency Specializations
Comprehensive recruitment strategies for all phenotypes and manifestations of AATD.
Severe AATD (ZZ Phenotype)
Most severe deficiency requiring aggressive treatment
- Augmentation therapy trials
- Lung transplant studies
- Gene therapy research
Moderate AATD (SZ Phenotype)
Intermediate deficiency with variable symptoms
- Progression monitoring
- Prevention studies
- Quality of life assessments
AATD-Related Emphysema
Lung damage from alpha-1 antitrypsin deficiency
- Bronchodilator studies
- Anti-inflammatory trials
- Surgical interventions
AATD Liver Disease
Hepatic manifestations of alpha-1 deficiency
- Hepatoprotective studies
- Liver function monitoring
- Transplant protocols
Pediatric AATD
Children with early-onset alpha-1 deficiency
- Growth monitoring
- Early intervention
- Family screening studies
Augmentation Therapy
Patients receiving or eligible for replacement therapy
- Dosing optimization
- Efficacy studies
- Long-term safety monitoring